Body Exfoliant Regulatory Compliance: Microplastic-Free & EU Rinse-Off Regulation

Overview #

Microplastic restrictions are not coming — they are already here, and the EU enforcement timeline is tighter than most brand owners realize. If you are developing a body scrub, exfoliating wash, or rinse-off treatment for European retail, the window to reformulate with compliant alternatives is narrowing fast. We have been working through this transition with brand partners since the ECHA restriction proposal entered its final assessment phase, and the formulation challenges are real. This guide covers what we actually see on the compliance side — EU, FDA, and NMPA — and what documentation we prepare before a single unit ships.

EU Microplastic Restriction: What the Regulation Actually Says #

The EU restriction on intentionally added microplastics under EU Cosmetics Regulation 1223/2009 and the broader REACH framework (Commission Regulation EU 2023/2055) is the one that catches brands off guard. The restriction covers synthetic polymer particles below 5mm in any dimension that are not biodegradable, not water-soluble, and not naturally occurring. For rinse-off cosmetics — body scrubs, exfoliating gels, cleansing grains — the transition period ended October 17, 2023 for most solid microplastic beads. Glitter and other encapsulated formats have staggered timelines running to 2027 and 2035 depending on application.

What this means practically: polyethylene beads, polypropylene granules, and nylon-12 particles in rinse-off formats are no longer compliant for EU market entry. We stopped accepting briefs with these materials for EU-destined products in early 2023. The replacement landscape is not simple. Jojoba esters, cellulose beads, walnut shell powder, apricot kernel powder, and sugar-based exfoliants each behave differently in emulsion systems, and not all of them are drop-in substitutes at the same loading level.

One thing we push back on regularly: brands assume that switching to a “natural” exfoliant automatically resolves the compliance question. It does not. The restriction is defined by polymer chemistry and biodegradability criteria, not by whether the ingredient sounds natural. Some bio-based polymers still fall under the restriction if they do not meet the biodegradation threshold. We now require suppliers to provide biodegradation data — specifically OECD 301 or equivalent — before we approve any polymeric exfoliant for EU-bound formulations.

The SCCS Scientific Opinion on microplastics in cosmetics is worth reading if you want to understand the toxicological basis. Most brand owners don’t. We do, because it shapes how we write the safety assessment.

US FDA Position: A Different Problem Entirely #

The US regulatory picture is structurally different. The Microbead-Free Waters Act of 2015 already banned plastic microbeads — specifically polyethylene, polypropylene, polyethylene terephthalate, and nylon — in rinse-off cosmetics and non-prescription drugs. That law has been in effect since July 2017 for manufacturing and July 2018 for interstate commerce. So for most conventional synthetic bead formats, the US market has been restricted longer than the EU.

What the FDA Cosmetics Guidelines do not cover is the broader category of synthetic polymers that are not technically “microbeads” under the statutory definition. Acrylate copolymers used as film formers, certain silicone-based exfoliants, and encapsulated actives in polymeric shells occupy a grey zone that the Microbead-Free Waters Act does not explicitly address. We are still not convinced the FDA’s current framework is adequate for the next generation of synthetic exfoliant materials, and we tell brand partners this directly when they ask about long-term compliance risk.

Labeling under FDA is straightforward for cosmetics: ingredient declaration under INCI nomenclature, net weight, manufacturer or distributor information, and any required warnings. For OTC drug-cosmetic combinations — an exfoliating body wash with salicylic acid at 0.5–2%, for example — the Drug Facts panel requirement kicks in, and that changes the entire documentation and registration approach. We have seen brands underestimate this. A body scrub with 1% salicylic acid is not a cosmetic in the US. It is an OTC drug. The compliance pathway is completely different.

China NMPA: Registration vs. Filing, and Why It Matters for Timelines #

China’s framework under the NMPA Cosmetic Regulation divides cosmetics into “special use” (特殊化妆品) and “ordinary” (普通化妆品) categories. Body exfoliants without active drug claims fall under ordinary cosmetics, which means filing rather than registration — a meaningful difference in timeline. Filing for imported ordinary cosmetics through the NMPA electronic system typically runs 3–6 months from submission to approval, assuming the dossier is complete on first submission. Registration for special-use products runs 12–18 months or longer.

China does not have a specific microplastic restriction equivalent to EU 2023/2055 as of our last dossier submission in Q1 2025. However, the NMPA’s Cosmetic Ingredient Safety Technical Guidelines require a safety assessment for any ingredient not on the Inventory of Existing Cosmetic Ingredients in China (IECIC). If you are using a novel bio-based exfoliant that is not on the IECIC list, you are looking at a new ingredient notification process that adds 6–12 months to your timeline. We have had two projects stall at this exact point — once with a fermented cellulose bead and once with a novel sugar-derived exfoliant from a European supplier. Both required supplementary toxicological data packages before NMPA would accept the filing.

Labeling in China requires Mandarin Chinese on the primary display panel, NMPA filing number, manufacturer information, and full ingredient list in descending order. For imported products, the Chinese responsible person (境内责任人) must be designated before filing. We help brand partners identify and contract with a qualified responsible person as part of our documentation service.

Where Most Brands Get This Wrong #

Honestly, the biggest compliance failure we see is not choosing the wrong exfoliant. It is treating regulatory compliance as a post-formulation step.

We had one project — a European indie brand, body polish with walnut shell powder at 8% and a fragrance blend at 1.2% — where the formulation was finalized, packaging was ordered, and then the brand asked us to prepare the EU safety assessment. The fragrance blend contained a restricted allergen above the rinse-off threshold under Annex III of the EU Cosmetics Regulation. The fragrance had to be reformulated. That pushed the launch by 11 weeks and cost the brand roughly €4,000 in reformulation and retesting fees. Not catastrophic, but entirely avoidable.

The other failure mode we see regularly: brands request a single formulation for global launch without understanding that the same product may require different INCI declarations, different labeling formats, and in some cases different concentrations for different markets. A body exfoliant with 2% salicylic acid is an OTC drug in the US, a cosmetic in the EU (below the 2% limit for rinse-off), and requires special-use registration in China. Three different compliance pathways. One formulation. This is usually where projects go sideways.

A clinical note worth including here: a randomized, double-blind, split-body study (n=42, 8 weeks, twice-weekly application) comparing a jojoba ester exfoliant at 5% against a polyethylene bead control at the same loading level showed equivalent IGA score improvement (31% vs. 33% reduction in rough texture score) with no statistically significant difference in skin barrier disruption as measured by TEWL. The jojoba ester formulation showed slightly higher consumer preference scores on sensory evaluation (68% vs. 54% preference). This is the kind of data we use to support efficacy claims in safety assessments — not to make marketing claims, but to demonstrate that the compliant alternative performs comparably.

Market Compliance Comparison #

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when a body exfoliant brief comes in. The answers determine everything — not just the exfoliant choice, but the preservative system, the pH target, the fragrance loading limit, and the documentation package we build.

For EU-only launches, we default to jojoba esters at 3–6% or cellulose beads at 4–8% as primary exfoliants, depending on the texture target. Both are OECD 301-compliant on biodegradation. We run a full Annex I safety assessment with a qualified EU safety assessor — this is not optional and it is not something we cut corners on. CPNP notification is handled before any product enters EU commerce.

For US launches with salicylic acid, we flag the OTC drug pathway on day one. If the brand wants to avoid the Drug Facts panel, we keep salicylic acid below 0.5% and position it as a cosmetic ingredient, not an active. Most brands prefer this route.

For China, we start the IECIC check before finalizing the ingredient list. If anything is not on the inventory, we discuss the timeline impact immediately. We have learned — sometimes the hard way — that discovering a novel ingredient issue at dossier submission stage is expensive. We also coordinate the responsible person designation early, because that process takes longer than brands expect.

For global launches, we build a compliance matrix at brief stage. It adds time upfront. It saves significantly more time later.

See also our documentation on acid exfoliation technology and barrier repair and sensitive skin formulation for related formulation considerations.

Frequently Asked Questions #

Q: We want to use a “natural” walnut shell scrub — does that automatically pass EU microplastic rules?

Yes, walnut shell powder (INCI: Juglans Regia Shell Powder) is not a synthetic polymer and is not covered by the EU 2023/2055 restriction. However, we still run a particle size and morphology check — sharp-edged particles above certain sizes have drawn attention from dermatology bodies, and some EU retailers have their own supplier requirements beyond the regulatory minimum. It is not a compliance issue, but it can be a retailer listing issue.

Q: How long does NMPA filing take for a body scrub with no special-use claims?

For an ordinary cosmetic filing with a complete dossier, we typically see approval in 3–6 months. The variable is dossier completeness on first submission. If NMPA issues a supplementary information request (补充资料), add 2–3 months. We have had clean filings approved in 14 weeks and complicated ones take 9 months. The IECIC check upfront is the single biggest factor in avoiding delays.

Q: Can we use the same formula for EU and US without any changes?

Usually yes for the formulation itself, but the documentation, labeling, and compliance pathway are different. If your formula contains salicylic acid at 0.5% or above, the US requires OTC drug registration and a Drug Facts panel — the EU does not. If your formula contains any fragrance allergens above rinse-off thresholds, EU labeling requires individual declaration of 26 listed allergens. The US does not require this. Same formula, different paperwork.

Q: What is the EU safety assessor requirement — can we use our own?

Under Article 10 of EU Cosmetics Regulation 1223/2009, the safety assessment must be performed by a person with a degree in pharmacy, toxicology, medicine, or a related discipline. If your assessor meets that qualification, yes. In practice, most of our brand partners use our contracted EU safety assessor network, which covers assessments for €800–€1,500 per SKU depending on complexity. We include this in our documentation package.

Q: We heard microplastic rules are coming to the US too — should we reformulate now?

The US regulatory picture is moving, but slowly. There is no federal restriction beyond the 2015 Microbead-Free Waters Act as of early 2025. Some states — California in particular — have broader environmental legislation that may affect certain polymer formats. If you are building a brand for long-term EU and US distribution, reformulating to EU-compliant exfoliants now is the right call. You avoid a second reformulation cycle, and the compliant alternatives — jojoba esters, cellulose, sugar-based exfoliants — perform well enough that there is no meaningful trade-off. We have not had a brand regret making the switch early.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.